More importantly, dioscin overcomes tyrosine kinase inhibitor resistance by down-regulating phosphatase SH2 domain-containing phosphatase-2 (SHP2) expression in EGFR-mutated lung adenocarcinoma cells 29. This evidence concerns the gene PTPN11 and lung adenocarcinoma.